伐度司他的适应症

Valostat is a new oral HIF-PH inhibitor, bringing a breakthrough treatment option for patients with anemia in dialysis-dependent chronic kidney disease. This article mainly analyzes the indication range, unique mechanism of action and contraindications of vadostat to help medical professionals and patients gain a deeper understanding of this innovative drug.

Indications of Valostat

It has a clear range of therapeutic indications and is accurately targeted at specific patient groups.

Core Indications

Valostat is specifically used to treat anemia caused by dialysis-dependent chronic kidney disease (CKD) in adults. Patients are required to have received regular dialysis treatment for at least 3 months. It stimulates endogenous erythropoietin production by simulating the physiological response of hypoxia.

Treatment Limitations

This drug is not suitable for blood transfusion replacement therapy that requires immediate correction of anemia, and is contraindicated in CKD patients who have not received dialysis. Clinical studies have shown that it does not improve patients' quality of life or fatigue symptoms.

Target hemoglobin level

It is necessary to maintain hemoglobin ≤11g/dL during treatment to avoid excessive hemoglobin levels that increase the risk of thrombosis. Dose adjustments need to be based on the results of hemoglobin monitoring every 2-4 weeks.

The scope of indications for vadostat is strictly limited and must be used under the guidance of a professional physician.

Efficacy and role of Valostat

Valostat exhibits multi-faceted therapeutic effects through its unique mechanism of action.

Physiological redness promotion effect

As a HIF-PH inhibitor, vadostat simulates the body's hypoxic state by stabilizing hypoxia-inducible factor, promoting endogenous EPO production, and improving iron metabolism utilization.

Reduce blood transfusion dependence

Clinical data show that vadostat can significantly reduce the need for blood transfusions in dialysis patients, and its efficacy is equivalent to that of traditional ESA, providing patients with the convenience of oral treatment.

Individualized treatment plan

The drug supports flexible dose adjustment (150-600mg/day), and personalized treatment plans can be formulated based on the patient's iron status, liver function and other indicators.

Valadostat's multiple mechanisms of action provide a more physiological treatment option for dialysis anemia patients.

Contraindications of Valadostat

Patients need to clarify the contraindications of the drug before taking the drug. Patients with contraindications should avoid taking the drug.

Absolute contraindications

Strictly contraindicated in non-dialysis patients as it may increase the risk of death and stroke. Use is contraindicated in patients with cirrhosis or acute liver disease. Safety data are lacking in patients with Child-Pugh Class C.

Relative contraindications

Use with caution in patients with cardiovascular events within 3 months. Pregnant women should only use it when clearly needed. Breast-feeding women should stop breastfeeding. Not allowed for children under 18 years old.

Drug interaction contraindications

Avoid co-administration with strong OAT1/OAT3 inhibitors, and take iron-containing drugs 1 hour apart. Dosage adjustments are required when using statins.

Strict compliance with contraindications can minimize the risks of treatment with vadostat.